NCT Number: NCT06491862
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Research Site, Belo Horizonte, Minas Gerais, Brazil
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with advanced/metastaic non-squamous NSCLC with or without AGA and who have failed platinum-based chemotherapy and immunotherapy (for patients without AGA) or platinum-based chemotherapy and at least 1 line of targeted therapy (for patients with AGA). The study will be conducted on one cohort of patients regardless their AGA status. The study index date will be defined as first dose of any agent after PTC, with specific treatments received for AGA and non-AGA patients in the preindex period. We will also conduct a subgroup analysis on NSCLC pre-defined subtypes (sample size permitting): EGFR mutant, ALK translocation, ROS1 translocation, MET1 mutant, HER-2 mutant, BRAF mutant, pan-wild-type PD-L1 >50%.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AGA Cohort: Presence of actionable mutations and all of the following:
Non-AGA Cohort: Absence of actionable mutations and all of the following:
Exclusion criteria
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: tumor histology, mutation and PD-L1 status, disease stage at diagnosis
Time frame: between January 1st 2017 and December 21th 2024
Description of patient population and treatment patterns: disease stage at diagnosis
Time frame: between January 1st 2017 and December 21th 2024
Description of patient population and treatment patterns: smoking status
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: age
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: gender
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: presence of brain metastasis at diagnosis
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: comorbidities (based on Charlson Comorbity Index)
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: treatments used prior to the index date, their start and end time and response
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: treatments used after the index date
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: weight
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: height
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: weight change between first treatment for metastatic disease and treatment index
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: starting dose of the index treatment
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: duration of therapy
Time frame: between January 1st 2017 and December 31th 2024
Description of patient population and treatment patterns: reasons for discontinuation
Interested in participating?
Request InfoAstraZeneca
Industry
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil
Acronym: RACE-2L
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06627647
Non-Squamous Non-Small Cell Lung Cancer
Mobile, Alabama, United States
View Trial DetailsNCT07005102
Neoplasms, Non-Squamous Non-Small Cell Lung Cancer
Chandler, Arizona, United States
View Trial DetailsNCT06868836
Non-Squamous Non-Small Cell Lung Cancer
Guangzhou, Guangdong, China
View Trial DetailsNCT07264816
Non-Squamous Non-Small Cell Lung Cancer
Wuhan, Hubei, China
View Trial Details